Novel paclitaxel-coated angioplasty balloon catheter based on cetylpyridinium salicylate: Preparation, characterization and simulated use in an in vitro vessel model

Development and in Vitro Characterization of Photochemically Crosslinked Polyvinylpyrrolidone Coatings for Drug-Coated Balloons

“…Although correlation to values reported in literature for DCB, already efficiently and safely applied in clinical routine, is only possible to a limited extent due to varying experimental conditions, crosslinked PVP seems a very promising novel matrix for PTX-delivering angioplasty balloon catheter. In a previous study, we have proposed the use of the ionic liquid cetylpyridinium salicylate as additive for DCB with equally promising results [27]. However, PVP is in contrast to ionic liquids already established as hydrophilic lubricious coating on catheter-based cardiovascular devices in order to ease movement through the vasculature.…”

“…Representative ESEM micrographs of DCB, coated via this strategy, reveal the successful integration of PTX crystals within the crosslinked hydrogel matrix (Figure 3). This seems essential for reduction of PTX wash off as we observed in a previous study that the presence of free PTX crystals above the coating matrix resulted in high drug wash off rates [27]. As we contrarily assume from our own and foreign previous investigations, that crosslinking density has an impact on drug release [28,29], resulting performance of photochemically crosslinked PVP coatings on DCB was again evaluated with regard to PTX wash off and transfer upon balloon expansion in a silicone tube as vessel model in dependence of UV radiation time.…”

“…For instance, Kelsch et al, and Scheller et al, reported a drug retention of 20% of initial PTX balloon load of 15-20 min and of 17% of initial PTX load of 40-60 min, post balloon dilatation, respectively [11,30]. As these studies dealt with DCB already efficiently and safely Moreover, in order to overcome lacking experimental set-up comparability, we additionally simulated the use of commercially available DCB with a urea-based coating, as we already reported previously [27]. With observed PTX drug transfer rates of 12%, the high potential of PVP as coating matrix for DCB with low drug loss and efficient drug transfer could be successfully underlined.…”

Acute drug transfer and particle release of drug coated balloons within a porcine in-vitro model

“…To reduce the drug loss during advancing the DCB to the final lesion and to improve drug transfer to the vessel wall, new drug coatings based on cetylpyridinium salycate (Cetpyrsal) or hyaluronic acid (HA) have been developed and tested in an in-vitro track model [5,6]. This model is limited in a way that artificial materials like Teflon or silicone are used to mimic the arterial walls in-vitro.…”

“…This study describes a method to gain information about the in-vivo drug transfer in a simple porcine in-vitro model, comparing a commercial available DCB with two alternative coatings developed by Petersen et al [5,6]. in Cetpyrsal.…”